Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers
Status:
Terminated
Trial end date:
2021-08-08
Target enrollment:
Participant gender:
Summary
HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for
the induction of remission in patients with acute promyelocytic leukemia (APL) and for the
treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs). This
phase 1 Trial is a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to
Evaluate the Safety, Tolerability and Pharmacokinetics of HF1K16.